Document Detail

Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells.
MedLine Citation:
PMID:  21431279     Owner:  NLM     Status:  MEDLINE    
Survivin is a member of the inhibitor of apoptosis protein family (IAP) that acts in both inhibition of apoptosis and regulation of the cell cycle. Despite the fact that survivin is overexpressed in almost all human malignancies, its expression is undetectable in most normal adult tissues, which is what makes it a potential target for anticancer interventions. The aim of this work was to investigate whether survivin is involved in resistance to idarubicin (ida), a drug commonly used in leukemia treatment. Cytotoxic assays using MTT showed that 1 µM of ida could inhibit 50% of cell viability in K562, a chronic myeloid leukemia cell line. Western blotting analysis revealed that survivin expression was increased in the cell line after treatment with ida 0.5 and 1 µM concentrations, protecting cells from ida-induced apoptosis. However, the highest ida concentrations tested were able to inhibit survivin levels and induce apoptosis in K562 cells, as evaluated by morphology and caspase-3 and -9 activation. These results indicate that survivin expression is involved in ida resistance in K562 leukemic cells. Flow cytometry analysis of the cell cycle showed that ida induced G2/M arrest in these cells and there was a statistically significant positive correlation between survivin expression and the percentage of cells in G2/M phase. This work supports the idea that survivin may contribute to an apoptosis-resistant phenotype by inhibiting ida-induced apoptosis and preventing cells from progressing in the cell cycle.
Gabriela Nestal de Moraes; Karina Lani Silva; Flavia da Cunha Vasconcelos; Raquel Ciuvalschi Maia
Related Documents :
20709949 - Neisseria lactamica selectively induces mitogenic proliferation of the naive b cell poo...
25278779 - Current understanding of the mechanisms for clearance of apoptotic cells-a fine balance.
21311599 - Overexpression of bmi-1 promotes cell growth and resistance to cisplatin treatment in o...
21235009 - Apoptosis in the uterotubal junction and oviductal isthmus during the estrous cycle of ...
1906879 - Biosynthetic maturation of an ascites tumor cell surface sialomucin. evidence for o-gly...
22562359 - Lentiviral vector-mediated shrna against aimp2-dx2 suppresses lung cancer cell growth t...
21756269 - Role of the non-canonical notch ligand dlk1 in hormone-producing cells of the adult mal...
2475069 - Survival of vibrio anguillarum and vibrio salmonicida at different salinities.
2317809 - Cellular f-actin levels as a marker for cellular transformation: relationship to cell d...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-03-22
Journal Detail:
Title:  Oncology reports     Volume:  25     ISSN:  1791-2431     ISO Abbreviation:  Oncol. Rep.     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-04-19     Completed Date:  2011-08-08     Revised Date:  2011-08-19    
Medline Journal Info:
Nlm Unique ID:  9422756     Medline TA:  Oncol Rep     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1613-9     Citation Subset:  IM    
Laboratório de Hemato-Oncologia Celular e Molecular, Programa de Pesquisa em Hemato-Oncologia Molecular, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology
Apoptosis / genetics*
Blotting, Western
Cell Cycle / drug effects
Cell Line, Tumor
Drug Resistance, Neoplasm / genetics*
Idarubicin / pharmacology
Inhibitor of Apoptosis Proteins / biosynthesis*,  genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*,  metabolism
Reg. No./Substance:
0/Antineoplastic Agents; 0/BIRC5 protein, human; 0/Inhibitor of Apoptosis Proteins; 58957-92-9/Idarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The DPP-IV inhibitor ER-319711 has a proliferative effect on the colonic epithelium and a minimal ef...
Next Document:  Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma.